{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"59"}],"units":"Participants"}],"description":"Incidence of adrenal cortical adenomas as assessed by non-contrast MRI of the abdomen (CT or ultrasound of the abdomen was permitted if MRI was contraindication)","groups":[{"description":"This was a follow-up safety study where study treatment was not administered. Patients came from BGG492 studies where patients were previously exposed to \\> 28 days of BGG492 50 mg, 100 mg or 150 mg given orally three times a day","id":"OG000","title":"BGG492"}],"paramType":"NUMBER","populationDescription":"Full analysis Set: included all patients who signed informed consent to enter the study","reportingStatus":"POSTED","timeFrame":"Minimum of one year after last dose of BGG492 in study BGG492A2207 or BGG492A2212","title":"Incidence of Adrenal Cortical Adenomas","type":"PRIMARY","unitOfMeasure":"Particpants"}